€45.85
0.76% today
Paris, Nov 14, 05:35 pm CET
ISIN
FR001400Q9V2
Symbol
EXENS

Exosens Target price 2025 - Analyst rating & recommendation

Exosens Classifications & Recommendation:

Buy
78%
Hold
17%
Sell
6%

Exosens Price Target

Target Price €48.96
Price €45.85
Potential
Number of Estimates 13
13 Analysts have issued a price target Exosens 2026 . The average Exosens target price is €48.96. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 14 Analysts recommend Exosens to buy, 3 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Exosens stock has an average upside potential 2026 of . Most analysts recommend the Exosens stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million € 394.08 481.70
35.04% 22.23%
EBITDA Margin 26.93% 30.47%
1.13% 13.13%
Net Margin 7.79% 16.24%
23.40% 108.60%

13 Analysts have issued a sales forecast Exosens 2025 . The average Exosens sales estimate is

€482m
Unlock
. This is
11.58% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€498m 15.29%
Unlock
, the lowest is
€451m 4.42%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 €394m 35.04%
2025
€482m 22.23%
Unlock
2026
€547m 13.64%
Unlock
2027
€609m 11.23%
Unlock
2028
€695m 14.20%
Unlock
2029
€778m 11.83%
Unlock

11 Analysts have issued an Exosens EBITDA forecast 2025. The average Exosens EBITDA estimate is

€147m
Unlock
. This is
15.36% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€159m 24.77%
Unlock
, the lowest is
€124m 2.18%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 €106m 36.57%
2025
€147m 38.30%
Unlock
2026
€168m 14.18%
Unlock
2027
€187m 11.72%
Unlock
2028
€230m 22.60%
Unlock
2029
€254m 10.59%
Unlock

EBITDA Margin

2024 26.93% 1.13%
2025
30.47% 13.13%
Unlock
2026
30.62% 0.49%
Unlock
2027
30.76% 0.46%
Unlock
2028
33.02% 7.35%
Unlock
2029
32.65% 1.12%
Unlock

13 Exosens Analysts have issued a net profit forecast 2025. The average Exosens net profit estimate is

€78.2m
Unlock
. This is
40.36% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€102m 82.74%
Unlock
, the lowest is
€63.2m 13.40%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 €30.7m 66.65%
2025
€78.2m 154.95%
Unlock
2026
€95.3m 21.78%
Unlock
2027
€111m 16.04%
Unlock

Net Margin

2024 7.79% 23.40%
2025
16.24% 108.60%
Unlock
2026
17.40% 7.14%
Unlock
2027
18.16% 4.37%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share 0.74 1.54
105.56% 108.11%
P/E 29.99
EV/Sales 5.22

13 Analysts have issued a Exosens forecast for earnings per share. The average Exosens EPS is

€1.54
Unlock
. This is
41.28% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
€2.01 84.40%
Unlock
, the lowest is
€1.24 13.76%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 €0.74 105.56%
2025
€1.54 108.11%
Unlock
2026
€1.88 22.08%
Unlock
2027
€2.18 15.96%
Unlock

P/E ratio

Current 42.39 0.89%
2025
29.99 29.24%
Unlock
2026
24.63 17.87%
Unlock
2027
21.22 13.84%
Unlock

Based on analysts' sales estimates for 2025, the Exosens stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.82 181.16%
2025
5.22 10.32%
Unlock
2026
4.59 12.00%
Unlock
2027
4.13 10.09%
Unlock
2028
3.62 12.43%
Unlock
2029
3.23 10.58%
Unlock

P/S ratio

Current 5.41 196.37%
2025
4.85 10.38%
Unlock
2026
4.27 12.00%
Unlock
2027
3.84 10.09%
Unlock
2028
3.36 12.43%
Unlock
2029
3.00 10.58%
Unlock

Current Exosens Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
STIFEL EUROPE
Locked
Locked
Locked Sep 08 2025
MIDCAP PARTNERS
Locked
Locked
Locked Aug 28 2025
ODDO BHF
Locked
Locked
Locked Aug 01 2025
STIFEL EUROPE
Locked
Locked
Locked Jul 15 2025
STIFEL EUROPE
Locked
Locked
Locked Jul 14 2025
MIDCAP PARTNERS
Locked
Locked
Locked May 19 2025
MIDCAP PARTNERS
Locked
Locked
Locked May 18 2025
Analyst Rating Date
Locked
STIFEL EUROPE:
Locked
Locked
Sep 08 2025
Locked
MIDCAP PARTNERS:
Locked
Locked
Aug 28 2025
Locked
ODDO BHF:
Locked
Locked
Aug 01 2025
Locked
STIFEL EUROPE:
Locked
Locked
Jul 15 2025
Locked
STIFEL EUROPE:
Locked
Locked
Jul 14 2025
Locked
MIDCAP PARTNERS:
Locked
Locked
May 19 2025
Locked
MIDCAP PARTNERS:
Locked
Locked
May 18 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today